We work with biotechnology and technology companies, philanthropic supporters, research colleagues and policymakers to accelerate scientific advances and extend the reach of our discoveries. It can take a decade or more for a new medicine to evolve from a finding in a research lab through clinical trials and approval. Our alliances help expedite the process by combining the financial, scientific and business expertise of multiple collaborators.
Bristol Myers Squibb is funding preclinical and clinical research at Fred Hutch to develop the next generation of cancer immunotherapies. The collaboration continues efforts established under Juno Therapeutics, now Bristol Myers Squibb. Juno was founded in 2013 as a collaboration between Fred Hutch, Memorial Sloan Kettering Cancer Center and Seattle Children’s Research Institute, combining cutting-edge immunotherapy expertise from all three institutions.
Takeda is global pharmaceutical company based in Japan that develops new therapeutic drugs in the areas of oncology, gastroenterology and neuroscience. In 2018, Takeda entered into a research alliance with Fred Hutch, the University of Washington and Seattle Children’s Research Institute to take promising biological targets and accelerate development of candidate drugs that can benefit patients. The collaboration is known as the Seattle Partnership for Research on Innovative Therapies (SPRInT).
Discoveries made in Fred Hutch labs have led to dozens of licensing agreements and startup businesses, including biotechnology companies that are developing cutting-edge therapies and diagnostics.